InsidersTradesSigma
Track the Guardant Health, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Guardant Health, Inc. has published 596 reports. Market capitalisation: €2.4bn. The latest transaction was filed on 27 August 2026 (J). Among the most active insiders: Talasaz AmirAli. The full history is openly available.
596
Insider Decl.
n/a
Thresholds
€9m
7 ops.
Buy Volume
€64m
83 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Guardant Health, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
57Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,881 of 29,063 companies
29.1
score / 100
Value24
Quality34
FCF yld-3.8%
Earn yld-4.8%
EV/EBITDA·
ROE-40%
Gross mgn64%
Net mgn-11%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 August 2026
Declarations596 total
25,000 shares0Common StockSEC:0001752968-26-000016:0
25,000 shares0Common StockSEC:0001752968-26-000016:1
30,000 shares0Common StockSEC:0001752968-26-000016:2
264 shares0Common StockSEC:0001258394-26-000016:0
7,589 shares@ US$170.28620.056% mcap2.1% of flowCommon StockSEC:0001753159-26-000020:2
9,023 shares@ US$168.19580.065% mcap2.5% of flowCommon StockSEC:0001753159-26-000020:0
20,888 shares@ US$169.16180.15% mcap5.8% of flowCommon StockSEC:0001753159-26-000020:1
37,500 shares@ US$169.15690.27% mcap11.6% of flowCommon StockSEC144:0001972481-26-000267
232 shares0Common StockSEC:0001865525-26-000026:0
250 shares0Common StockSEC:0001968281-26-000023:0
116 shares@ US$156.450.0008% mcap2.5% of flowCommon StockSEC:0001968281-26-000023:1
116 shares@ US$156.44830.0008% mcap2.6% of flowCommonSEC144:0001921094-26-000884
32,288 shares@ US$20.140.028% mcap3.5% of flowCommon StockSEC:0001652956-26-000018:0
14,012 shares@ US$28.610.017% mcap2.1% of flowCommon StockSEC:0001652956-26-000018:1
3,704 shares@ US$163.41410.026% mcap3.2% of flowCommon StockSEC:0001652956-26-000018:2
9,934 shares@ US$164.27120.070% mcap8.7% of flowCommon StockSEC:0001652956-26-000018:3
13,248 shares@ US$166.10690.095% mcap11.8% of flowCommon StockSEC:0001652956-26-000018:5
400 shares@ US$167.91880.0029% mcap0.4% of flowCommon StockSEC:0001652956-26-000018:6
19,014 shares@ US$165.15780.14% mcap16.8% of flowCommon StockSEC:0001652956-26-000018:4
46,300 shares@ US$165.12350.33% mcap76.7% of flowCommonSEC144:0001921094-26-000839
35,000 shares0Common StockSEC:0001752968-26-000014:0
35,000 shares0Common StockSEC:0001752968-26-000014:1
75,000 shares0Common StockSEC:0001753159-26-000018:0
75,000 shares0Common StockSEC:0001753159-26-000018:1
800 shares0Common StockSEC:0001737840-26-000020:0
25 of 596 declarations
关于 Guardant Health, Inc.
Guardant Health, Inc. 是一家美国精准肿瘤学和液体活检公司，在纳斯达克上市，股票代码为 GH。该公司总部位于美国加利福尼亚州帕洛阿尔托，成立于 2012 年，已建立一个差异化平台，专注于利用血液检测、组织检测、临床数据集和人工智能分析，帮助临床医生更有效地检测、表征和监测癌症。它已成为肿瘤分子诊断领域最知名的公司之一。([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Surpasses-500-Peer-Reviewed-Publications-Milestone/default.aspx?utm_source=openai)) Guardant 的商业模式围绕三个主要支柱展开。肿瘤学部门包括针对晚期和早期癌症患者的液体和组织基因组检测。筛查部门专注于癌症筛查，最著名的是 Shield，该公司用于结直肠癌筛查的血液检测。生物制药与数据业务通过为制药合作伙伴提供真实世界的临床基因组数据和相关服务来创收，支持药物开发和伴随诊断的创建。产品组合中的主要产品包括 Guardant360 Liquid、Guardant360 CDx、Guardant360 Tissue、Guardant Reveal 和 Shield。([about.guardanthealth.com](https://about.guardanthealth.com/products/tests-for-patients-with-early-and-advanced-stage-cancer/?utm_source=openai)) 从竞争角度来看，Guardant Health 是液体活检领域的全球领导者之一。其优势来自于其数据资产的规模和深度、科学出版记录、主要癌症中心的临床应用，以及将检测方法纳入 FDA 批准的伴随诊断角色和报销途径的能力。该公司在 2024 年表示，其技术已在 500 多篇同行评审出版物中得到专题报道，这突显了其在竞争激烈的领域中的科学可信度。([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Surpasses-500-Peer-Reviewed-Publications-Milestone/default.aspx?utm_source=openai)) 最近的里程碑意义重大。2026 年 1 月，Guardant 获得了 Guardant360 CDx 的额外 FDA 批准，包括用于 BRAF V600E 突变转移性结直肠癌，并于 2026 年 5 月 4 日获得用于 ESR1 突变 ER+/HER2- 晚期乳腺癌的批准。2026 年 3 月，Shield 通过 Quest Diagnostics 的全国订购和收集网络变得更广泛地可用。Guardant 还于 2026 年 1 月宣布与默克公司建立为期多年的战略合作，加强了该公司的伴随诊断和智能平台战略。在其 2026 年展望中，该公司预计全年收入为 1.25 billion 至 1.28 billion 美元。([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-Receives-FDA-Approval-for-Guardant360-CDx-as-Companion-Diagnostic-for-BRAFTOVI-encorafenib-Combination-in-Patients-with-BRAF-V600E-Mutant-Metastatic-Colorectal-Cancer/default.aspx?utm_source=openai)) 对于法国、比利时和瑞士的投资者而言，Guardant Health 仍然是一个具有强大战略定位的成长型医疗保健公司，但它仍依赖于商业执行、报销范围的扩大以及血液癌症诊断在美国纳斯达克市场更广泛的临床应用。
